Dimension Therapeutics Inc. (NASDAQ:DMTX) – Investment analysts at Jefferies Group cut their FY2016 earnings per share (EPS) estimates for shares of Dimension Therapeutics in a research note issued on Thursday. Jefferies Group analyst G. Wang now forecasts that the firm will post earnings per share of ($2.04) for the year, down from their previous forecast of ($1.99). Jefferies Group has a “Buy” rating and a $12.00 price objective on the stock. Jefferies Group also issued estimates for Dimension Therapeutics’ Q4 2016 earnings at ($0.60) EPS, FY2017 earnings at ($2.26) EPS, FY2018 earnings at ($1.36) EPS, FY2019 earnings at ($1.72) EPS and FY2020 earnings at ($1.24) EPS.

DMTX has been the subject of several other research reports. Zacks Investment Research raised shares of Dimension Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, October 25th. Canaccord Genuity set a $20.00 price objective on shares of Dimension Therapeutics and gave the stock a “buy” rating in a research report on Thursday, August 11th. Finally, Chardan Capital set a $10.00 price objective on shares of Dimension Therapeutics and gave the stock a “hold” rating in a research report on Sunday, August 21st. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Dimension Therapeutics has a consensus rating of “Buy” and a consensus target price of $15.21.

Dimension Therapeutics (NASDAQ:DMTX) opened at 5.75 on Monday. The firm’s market capitalization is $143.92 million. Dimension Therapeutics has a 12-month low of $4.00 and a 12-month high of $15.55. The firm has a 50 day moving average of $6.53 and a 200 day moving average of $7.11.

Several institutional investors have recently modified their holdings of the company. FIL Ltd bought a new position in shares of Dimension Therapeutics during the second quarter valued at $10,133,000. Vanguard Group Inc. boosted its position in shares of Dimension Therapeutics by 447.4% in the second quarter. Vanguard Group Inc. now owns 426,165 shares of the company’s stock valued at $2,557,000 after buying an additional 348,311 shares during the period. BlackRock Fund Advisors boosted its position in shares of Dimension Therapeutics by 119.2% in the second quarter. BlackRock Fund Advisors now owns 317,232 shares of the company’s stock valued at $1,903,000 after buying an additional 172,495 shares during the period. JPMorgan Chase & Co. boosted its position in shares of Dimension Therapeutics by 50.5% in the first quarter. JPMorgan Chase & Co. now owns 239,000 shares of the company’s stock valued at $1,871,000 after buying an additional 80,200 shares during the period. Finally, Spark Investment Management LLC bought a new position in shares of Dimension Therapeutics during the second quarter valued at $367,000. Institutional investors own 85.52% of the company’s stock.

About Dimension Therapeutics

Dimension Therapeutics, Inc is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa).

5 Day Chart for NASDAQ:DMTX

Receive News & Stock Ratings for Dimension Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dimension Therapeutics Inc. and related stocks with our FREE daily email newsletter.